Developments in chemical approaches to treat tuberculosis in the last decade
- PMID: 22204345
- DOI: 10.2174/092986712798918815
Developments in chemical approaches to treat tuberculosis in the last decade
Abstract
Tuberculosis (TB) caused by Mycobacterium tuberculosis claims millions of lives each year globally. Although it can be controlled by currently available drug regimen (DOTS), yet the emergence of multidrug resistance (MDR) and extensively drug resistance (XDR) TB is a growing concern. The increasing rate of MDR-TB, co-infection with HIV and XDR-TB necessitates the development of new anti-TB agents that have a practical impact on tuberculosis control. This review article gives a brief introduction of tuberculosis, present day problems, traditional and new anti-TB drug targets, currently used drugs, their mode of action, the pipeline compounds and a short description of new chemical entities (NCE's) as antitubercular agents developed in last 10 years.
Similar articles
-
Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.Org Biomol Chem. 2016 Jan 28;14(4):1177-87. doi: 10.1039/c5ob02298c. Epub 2015 Dec 8. Org Biomol Chem. 2016. PMID: 26645944 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43. MMWR Recomm Rep. 2009. PMID: 19214162
-
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.Chem Biol Drug Des. 2021 Nov;98(5):787-827. doi: 10.1111/cbdd.13934. Epub 2021 Sep 16. Chem Biol Drug Des. 2021. PMID: 34397161 Review.
-
Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.Infect Disord Drug Targets. 2015;15(1):32-41. doi: 10.2174/1871526514666140923153329. Infect Disord Drug Targets. 2015. PMID: 25246035 Review.
Cited by
-
Strategies of Pathogens to Escape from NO-Based Host Defense.Antioxidants (Basel). 2022 Nov 3;11(11):2176. doi: 10.3390/antiox11112176. Antioxidants (Basel). 2022. PMID: 36358549 Free PMC article. Review.
-
Serum protein gamma-glutamyl hydrolase, Ig gamma-3 chain C region, and haptoglobin are associated with the syndromes of pulmonary tuberculosis in traditional Chinese medicine.BMC Complement Altern Med. 2015 Jul 22;15:243. doi: 10.1186/s12906-015-0686-4. BMC Complement Altern Med. 2015. PMID: 26198726 Free PMC article.
-
Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N.PLoS One. 2013 Aug 1;8(8):e69762. doi: 10.1371/journal.pone.0069762. Print 2013. PLoS One. 2013. PMID: 23936350 Free PMC article.
-
Microarray expression profile analysis of mRNAs and long non-coding RNAs in pulmonary tuberculosis with different traditional Chinese medicine syndromes.BMC Complement Altern Med. 2016 Nov 17;16(1):472. doi: 10.1186/s12906-016-1436-y. BMC Complement Altern Med. 2016. PMID: 27855662 Free PMC article.
-
Protective immune mechanisms of Yifei Tongluo, a Chinese herb formulation, in the treatment of mycobacterial infection.PLoS One. 2018 Sep 11;13(9):e0203678. doi: 10.1371/journal.pone.0203678. eCollection 2018. PLoS One. 2018. PMID: 30204794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical